Navigation Links
Nasal polyps from analgesics
Date:3/10/2008

If a patient develops respiratory problems after taking analgesics, this indicates that the active substances are poorly tolerated. This is pointed out by Prof. Hanns-Wolf Baenkler, Erlangen University Medical School, in the current edition of the Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105(8): 13742). One should also think of analgesic intolerance when patients suffer from chronic irritation of the gastrointestinal tract, without any recognizable allergy or infection.

Patients with these symptoms exhibit enhanced sensitivity and changes in the pattern of the so-called eicosanoids - important mediators of pain and inflammation. This change in pattern explains the specific reaction to salicylates and related COX inhibitors in analgesics, cosmetics, and vegetable foods. The classical symptoms of intolerance are rhinitis, bronchial asthma or nasal polyps, accompanied by inflammatory reactions in the intestine or skin and urticaria.

The diagnosis is based on symptoms immediately after taking salicylates or on recurrent polyp formation. Blood tests can be an important diagnostic aid, particularly in difficult cases. Discontinuation of treatment helps, as does corticosteroid treatment. Biological treatment is also possible, based on adaptation by administering increasing doses of acetylsalicylic acid.


'/>"/>

Contact: Dr. Stephan Mertens
stephan.mertens@aerzteblatt.de
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related medicine news :

1. Saline Nasal Wash Helps Kids Fight Colds, Flu
2. Protein Nasal Spray Revives Sleep-Deprived Monkeys
3. Saline Irrigation Eases Chronic Nasal Symptoms
4. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
5. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
6. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
7. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
8. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
9. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
10. Nasal Anthrax Vaccine Proves Effective in Animal Study
11. Smoking can double risk of colorectal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: